文献速递炎症性肠病

乌司奴单抗与维得利珠单抗作为克罗恩病二线治疗的倾向性评分匹配真实世界比较:Cross Pennine 研究 II

A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II.
PubMed 文献 · Aliment Pharmacol Ther · 2021-12-22

这项回顾性研究在抗肿瘤坏死因子α治疗失败的克罗恩病患者中,比较乌司奴单抗与维得利珠单抗作为二线治疗的有效性和安全性。乌司奴单抗组14周临床缓解率70.9%,52周62.5%;倾向性评分匹配分析显示14周时乌司奴单抗临床缓解可能性比维得利珠单抗高38%(95%CI 25%-50%;P<0.001),52周时差异9%(95%CI -15%至33%;P=0.462)无统计学意义。

要点

  • 乌司奴单抗组14周临床应答或缓解率为70.9%(200/282),52周为62.5%(162/259)。
  • 倾向性评分匹配后,14周时乌司奴单抗临床缓解可能性较维得利珠单抗高38%(95%CI 25%-50%;P<0.001)。
  • 52周时两组临床缓解差异为9%(95%CI -15%至33%;P=0.462),无统计学意义。

核心结论

  • 乌司奴单抗在该真实世界队列中有效且耐受性良好,14周时疗效优于维得利珠单抗,但52周时与维得利珠单抗相比无统计学显著差异。

研究设计与样本

  • 回顾性分析,采用医师整体评估(PGA)评价乌司奴单抗在14周和52周的临床应答与缓解,并与维得利珠单抗队列进行倾向性评分匹配分析。
  • 乌司奴单抗组共282例患者(平均年龄40±15岁,女性与男性比例1.7:1);排除无既往抗TNFα暴露及既往使用过维得利珠单抗或乌司奴单抗的患者后,分析乌司奴单抗组275/282例(97.5%)和维得利珠单抗组118/135例(87.4%)。

主要发现

  • 乌司奴单抗组14周临床应答或缓解率为70.9%(200/282),52周为62.5%(162/259)。
  • 共发生74例不良事件,其中26例被判定为严重不良事件(8.3/100人年)。
  • 倾向性评分分析显示,14周时乌司奴单抗组达到临床缓解的可能性比维得利珠单抗组高38%(95%CI 25%-50%;P<0.001)。
  • 52周时两组临床缓解差异为9%(95%CI -15%至33%;P=0.462),无统计学意义。

关键数值与推荐

  • 14周时乌司奴单抗组较维得利珠单抗组临床缓解可能性高38%(95%CI 25%-50%;P<0.001)。
  • 52周时乌司奴单抗组与维得利珠单抗组临床缓解差异为9%(95%CI -15%至33%;P=0.462),无统计学意义。
  • 乌司奴单抗组严重不良事件发生率为8.3/100人年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal choice of biological agents after failure of anti-tumour-necrosis-factor-(TNF)α agent in Crohn's disease (CD) is yet to be defined. AIMS: To assess the effectiveness and safety of ustekinumab compared to vedolizumab as second-line treatment in CD patients who failed anti-TNFα therapy. METHODS: Retrospective analysis of clinical response and remission at 14 and 52 weeks to ustekinumab by physician global assessment (PGA). A propensity score-matched analysis with a cohort treated with vedolizumab was performed. RESULTS: Of 282 patients (mean age 40 ± 15, F:M ratio 1.7:1) treated with ustekinumab, clinical response or remission was reached by 200/282 patients (70.9%) at 14 weeks, and 162/259 patients (62.5%) at 52 weeks. Overall, 74 adverse events occurred, of which 26 were labelled as serious (8.3 per 100 person-year). After exclusion of patients without prior anti-TNFα exposure and patients previously exposed to vedolizumab or ustekinumab, we analysed 275/282 patients (97.5%) on ustekinumab and 118/135 patients (87.4%) on vedolizumab. Propensity score analysis revealed that at 14 weeks, patients treated with ustekinumab were 38% (95% CI 25%-50%; P < 0.001) more likely to achieve clinical remission, while at 52 weeks, the difference of 9% (95% CI -15% to 33%; P = 0.462) was not significant. CONCLUSIONS: Ustekinumab was effective and well tolerated in this real-world cohort. While ustekinumab proved more effective at 14-weeks, we found no statistically significant differences at 52 weeks compared to vedolizumab.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lenti MV, Dolby V, Clark T, et al. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther. 2021. PMID: 34935160. doi:10.1111/apt.16742

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。